Vaderis Therapeutics Announces Oversubscribed $152 Million Series B Financing and Initiation of the Global Phase 3 HEROIC Study of Engasertib for Hereditary Hemorrhagic Telangiectasia
BASEL, Switzerland and LINCOLNSHIRE, Ill., Aug. 11, 2026, 07:00 GMT-04
VADERIS-THERAPEUTICS
Read full article →